Durability of peginterferon alfa‐2b treatment at 5 years in patients with hepatitis B e antigen–positive chronic hepatitis B
Vincent Wai‐Sun Wong, Grace Lai‐Hung Wong, Kenneth Kar‐Lung Yan, Angel Mei‐Ling Chim, Hoi‐Yun Chan, Chi‐Hang Tse, Paul Cheung‐Lung Choi, Anthony Wing‐Hung Chan, Joseph Jao‐Yiu Sung, Henry Lik‐Yuen Chan – 23 May 2010 – Approximately 30%‐40% of patients with hepatitis B e antigen (HBeAg)‐positive chronic hepatitis B treated with peginterferon and/or lamivudine achieve HBeAg seroconversion 6 months after the end of treatment. The durability and long‐term effect of treatment are unknown.